Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mol Biol Rep. 2021 Feb;48(2):1345-1357. doi: 10.1007/s11033-021-06193-4. Epub 2021 Feb 8.
Combination therapy has been considered as a potential method to overcome the BC chemoresistance. MicroRNAs (miRs) have been suggested as a therapeutic factor in the combination therapy of BC. This project aimed at examining the possible activity and molecular function of miR-424-5p and Taxol combination in the human BC cell line. MDA-MB-231 cells were treated with miR-424-5p mimics and Taxol, in a combined manner or separately. We used the MTT test for assessing the cell proliferation. In addition, flow-cytometry was used for evaluating apoptosis and cell-cycle. Expression levels of underlying molecular factors of miR-424-5p were assessed using western-blotting and qRT-PCR. The obtained results demonstrated that miR-424-5p repressed BC cell proliferation and sensitized these cells to Taxol treatment through the induction of apoptosis. Further investigations showed that miR-424-5p might increase BC chemosensitivity through the regulation of apoptosis-related factors including P53, Caspase-3, Bcl-2, and Bax as well as the proliferation-related gene c-Myc. Moreover, miR-424-5p restoration in combination with Taxol treatment decreased the colony formation by regulating Oct-4 and led to G2 arrest via modulating Cdk-2 expression. Western-blotting demonstrated that miR-424-5p may perform its anti-chemoresistance role by regulating the PD-L1 expression and controlling PTEN/PI3K/AKT/mTOR. Overall, the upregulation of miR-424-5p was indicated to upregulate the sensitivity of BC cells to treatment with Taxol. MiR-424-5p might regulate the chemosensitivity of the BC cell line by modulating PD-L1 and controlling the PTEN/mTOR axis. Therefore, the combination of miR-424-5p with Taxol would represent a novel procedure to treat against BC.
联合治疗被认为是克服乳腺癌化疗耐药性的一种潜在方法。microRNAs(miRs)已被认为是乳腺癌联合治疗的治疗因素。本项目旨在研究 miR-424-5p 和紫杉醇联合治疗人乳腺癌细胞系的可能活性和分子功能。MDA-MB-231 细胞用 miR-424-5p 模拟物和紫杉醇联合或单独处理。我们使用 MTT 试验评估细胞增殖。此外,流式细胞术用于评估细胞凋亡和细胞周期。使用 Western blot 和 qRT-PCR 评估 miR-424-5p 潜在分子因子的表达水平。研究结果表明,miR-424-5p 通过诱导细胞凋亡抑制乳腺癌细胞增殖,并使这些细胞对紫杉醇治疗敏感。进一步的研究表明,miR-424-5p 可能通过调节凋亡相关因子,包括 P53、Caspase-3、Bcl-2 和 Bax 以及增殖相关基因 c-Myc,来增加乳腺癌的化疗敏感性。此外,miR-424-5p 恢复与紫杉醇联合治疗通过调节 Oct-4 减少集落形成,并通过调节 Cdk-2 表达导致 G2 期阻滞。Western blot 表明,miR-424-5p 可能通过调节 PD-L1 的表达和控制 PTEN/PI3K/AKT/mTOR 来发挥其抗化疗耐药作用。总的来说,miR-424-5p 的上调表明可提高乳腺癌细胞对紫杉醇治疗的敏感性。miR-424-5p 可能通过调节 PD-L1 并控制 PTEN/mTOR 轴来调节乳腺癌细胞系的化疗敏感性。因此,miR-424-5p 与紫杉醇的联合治疗可能代表一种治疗乳腺癌的新方法。